Potential of statins for the treatment of multiple sclerosis

Lancet Neurol. 2003 Jan;2(1):9-10. doi: 10.1016/s1474-4422(03)00256-4.

Authors

David Baker¹, Peter Adamson, John Greenwood

Affiliation

¹ Neuroinflammation Group, Institute of Neurology, University College London, UK.

PMID: 12849290
DOI: 10.1016/s1474-4422(03)00256-4

No abstract available

MeSH terms

Adjuvants, Immunologic / pharmacology
Autoimmune Diseases / drug therapy
Autoimmune Diseases / prevention & control
Central Nervous System / pathology
Encephalomyelitis, Autoimmune, Experimental / drug therapy
Encephalomyelitis, Autoimmune, Experimental / prevention & control
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Leukocytes / drug effects
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / pathology

Substances

Adjuvants, Immunologic
Hydroxymethylglutaryl-CoA Reductase Inhibitors